HCPLive

Related Tags

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.

Most Popular

Recommended Reading

A positive family history is not a significant independent risk factor for breast cancer outcome, according to a study published online May 20 in the British Journal of Surgery.

High-value care advice has been provided for screening for five common types of cancer. The guidelines were published in the May 19 issue of the Annals of Internal Medicine.

For breast and colorectal cancer survivors, the level of exercise participation is significantly increased for those receiving an oncologist's exercise recommendations with an exercise motivation package, according to a study published online May 12 in Cancer.

Not all women with high breast density have high risk of interval cancer, according to a study published in the May 19 issue of the Annals of Internal Medicine.

$vAR$